Immutep Receives $3.4 million R&D tax incentive
- Immutep (IMM) is granted a $3.4 million research and development tax incentive from the French Government
- The biotechnology company saw €2,126,617 hit its pockets under the French Government’s Crédit d’Impôt Recherche scheme (CIR)
- The company says the funds will be used to support ongoing global clinical progress of its cancer and infectious disease treatment
- The company said it also qualified for cash rebates from the Australian Federal Government’s R&D tax incentive program
- Additionally, in April 2021 it received a $1,155,055 cash rebate for expenditure incurred on eligible R&D activities that took place during the 2020 fiscal year
- The company shares are trading 1.77 per cent down at 55.5 cents at 11:48 am AEST
